p16/CDKN2 Gene and p53 Gene Alterations in Japanese Non‐smoking Female Lung Adenocarcinoma

Primary lung adenocarcinomas in non‐smoking females are increasing in the USA and Japan. Environmental factors such as passive smoking, asbestos, domestic radon, and hormonal effects have been implicated, but the etiology is still uncertain. We therefore analyzed point mutations of p16 gene, a newly characterized tumor suppressor gene, and compared the results with alterations of p53 gene in 28 primary lung adenocarcinomas in non‐smoking Japanese females. There were no cases with somatic point mutation of p16 gene, except for one case with two germline mutations (silent mutations). In contrast, six out of 16 informative cases showed loss of heterozygosity of p53 gene using a TP53 microsatellite marker and 19 out of 28 cases showed expression of oncoprotein using DO‐7 immunohistochemistry. These findings suggest that p16 gene alteration is a rare event in primary lung adenocarcinomas in Japanese non‐smoking females, compared with alterations of the p53 gene.

[1]  M. Raffeld,et al.  Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. , 1995, Cancer research.

[2]  G. Hannon,et al.  Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. , 1995, Cancer research.

[3]  B. Tycko,et al.  MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. , 1995, The American journal of pathology.

[4]  A. Okamoto,et al.  IS-12 Mutation and altered expression of P16^ in human cancer. , 1995 .

[5]  A. Rustgi,et al.  MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. , 1995, Oncogene.

[6]  C. D. Edwards,et al.  Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.

[7]  R. Ueda,et al.  In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. , 1995, Cancer research.

[8]  G. Finocchiaro,et al.  Mutation rate of the CDKN2 gene in malignant gliomas. , 1994, Cancer research.

[9]  K. Kinzler,et al.  Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.

[10]  G. Reifenberger,et al.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.

[11]  J. Abraham,et al.  The MTS1 gene is frequently mutated in primary human esophageal tumors. , 1994, Oncogene.

[12]  C. James,et al.  CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. , 1994, Cancer research.

[13]  A. Okamoto,et al.  Mutations and altered expression of p16INK4 in human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Dosaka-akita,et al.  Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. , 1994, American journal of clinical pathology.

[15]  O. Olopade,et al.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.

[16]  D. Louis,et al.  Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. , 1994, Cancer research.

[17]  D Hoffmann,et al.  Smoking and lung cancer: scientific challenges and opportunities. , 1994, Cancer research.

[18]  A. Klein-Szanto,et al.  Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. , 1994, Cancer research.

[19]  L. Clark,et al.  Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes. , 1994, Cancer research.

[20]  R. Metcalf,et al.  p53 mutations in lung cancers from Japanese mustard gas workers. , 1994, Carcinogenesis.

[21]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[22]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[23]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[24]  M. Ogawa,et al.  Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. , 1994, Biochemical and biophysical research communications.

[25]  Peter A. Jones,et al.  P16 gene in uncultured tumours , 1994, Nature.

[26]  D. Sidransky,et al.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.

[27]  S. Mori,et al.  Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. , 1994, Cancer research.

[28]  E. Wynder,et al.  Re: Endocrine factors and adenocarcinoma of the lung in women. , 1994, Journal of the National Cancer Institute.

[29]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[30]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[31]  F. Askin,et al.  Frequent loss of chromosome 9 in human primary non-small cell lung cancer. , 1994, Cancer research.

[32]  C. Harris,et al.  p53: at the crossroads of molecular carcinogenesis and risk assessment. , 1993, Science.

[33]  Y. Takeshima,et al.  p53 mutations in lung cancers from non-smoking atomic-bomb survivors , 1993, The Lancet.

[34]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[35]  S. Goodman,et al.  Overexpression of the p53 Tumor Suppressor Gene Product in Primary Lung Adenocarcinomas Is Associated with Cigarette Smoking , 1993, The American journal of surgical pathology.

[36]  I. Baas,et al.  Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. , 1993, The American journal of pathology.

[37]  M. Skolnick,et al.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. , 1992, Science.

[38]  G. Gyapay,et al.  A second-generation linkage map of the human genome , 1992, Nature.

[39]  G. Lyman,et al.  Environmental tobacco smoke and lung cancer risk in nonsmoking women. , 1992, Journal of the National Cancer Institute.

[40]  Y. Nakamura,et al.  Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism , 1992, Genes, chromosomes & cancer.

[41]  R. Ueda,et al.  p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. , 1992, Cancer research.

[42]  R. Metcalf,et al.  Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. , 1991, Oncogene.

[43]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[44]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[45]  A. Churg,et al.  Pathology of Occupational Lung Disease , 1988 .

[46]  B. Vogelstein,et al.  Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. , 1985, Biochemical and biophysical research communications.

[47]  E. Radford,et al.  Lung cancer in Swedish iron miners exposed to low doses of radon daughters. , 1984, The New England journal of medicine.

[48]  A. Kaye,et al.  Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. , 1995, Cancer research.

[49]  K. Kikuchi,et al.  A Clinical Analysis of Lung Cancer in Women. , 1995 .

[50]  D. Lane,et al.  High levels of p53 protein in UV-irradiated normal human skin. , 1993, Oncogene.